PTC's Translarna: US FDA Opts For Simplicity When It Comes To Panel Questions
Executive Summary
Streamlined queries for third advisory committee review of a Duchenne muscular dystrophy drug ask only whether the data suggest ataluren is effective, may be effective but needs more study, or is not effective. In contrast, panelist had to muddle through seven discussion and voting questions for Sarepta's eteplirsen and nine for BioMarin's drisapersen.
You may also be interested in...
Exondys Revisited? Translarna Brings Efficacy Woes Into US Panel Review
FDA has twice refused to file PTC Therapeutics' NDA for the Duchenne muscular dystrophy treatment because of 'clearly and convincingly negative' pivotal trials and questionable post hoc analyses; sponsor argues ataluren should be afforded the same consideration and flexibility given to Sarepta's DMD drug eteplirsen, which received a controversial accelerated approval.
Translarna AdCom Has DMD Experience, But Most Opposed Approval Of Prior Applications
Several members of the Peripheral and Central Nervous System Drugs Advisory Committee meeting looking at PTC' Therapeutics' proposed Duchenne muscular dystrophy treatment also looked at Sarepta's Exondys 51 and BioMarin's Kyndrisa, but most did not vote or comment favorably.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.